For FY23, Amicus Therapeutics Is Increasing Galafold Revenue Growth Guidance To Between 16 And 18% At CER
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics has increased its revenue growth guidance for Galafold for FY23 to between 16% and 18% at CER.
November 08, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics' increased revenue growth guidance for Galafold for FY23 could potentially boost investor confidence and positively impact the company's stock price.
The increased revenue growth guidance indicates that Amicus Therapeutics expects higher sales of Galafold in FY23. This positive outlook could boost investor confidence in the company's future performance, potentially leading to an increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100